1-3 of 3
Christopher J. Molineaux, PhD
Close
Sort by
Journal Articles

The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration

Christopher J Kirk, Jing Jiang, Tony Muchamuel, Maya Dajee, Deborah Swinarski, Monette Aujay, Mark K Bennett, PhD, Jinfu Yang, Evan Lewis, Guy Laidig, Christopher J. Molineaux, PhD
Journal: Blood
Blood (2008) 112 (11): 2765.
https://doi.org/10.1182/blood.V112.11.2765.2765
Published: 2008
Journal Articles

Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.

Owen A. O’Connor, PhD, MD, Robert Z. Orlowski, MD, PhD, Melissa Alsina, MD, Keith Stewart, MBChB, Suzanne Trudel, MD, Marcy K. Vallone, Tina M. Woo, Pedro R. Urquilla, MD, Christopher J. Molineaux, PhD, Andre Goy, MD
Journal: Blood
Blood (2006) 108 (11): 2430.
https://doi.org/10.1182/blood.V108.11.2430.2430
Published: 2006
Journal Articles

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Christopher J. Kirk, PhD, Mark K. Bennett, PhD, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Mark N. Ho, BS, Jing Jiang, BS, Guy J. Laidig, PhD, Evan R. Lewis, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina M. Woo, BS, Christopher J. Molineaux, PhD
Journal: Blood
Blood (2005) 106 (11): 609.
https://doi.org/10.1182/blood.V106.11.609.609
Published: 2005